Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Adalimumab

            Therapeutic Area: Dermatology Product Name: Humira

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: AbbVie Inc

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 27, 2020

            Details:

            Approval is based on the data from a Japanese phase III clinical trial. The proportion of patients achieving at 100 of the target pyoderma gangrenosum ulcer area reduction at Week 26 of Humira administration was 54.5% in the trail.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sofpironium Bromide

            Therapeutic Area: Dermatology Product Name: Ecclock

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Brickell Biotech

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 25, 2020

            Details:

            Sofpironium bromide gel was deemed to be safe and well tolerated in this study, as well as in the accompanying 52-week long-term safety extension study in Japan. Japan is the first country to approve sofpironium bromide with commercial launch expected later this year.